Drug Discovery

From Bedside to Wall Street


  • Tamas Bartfai, PhD, The Scripps Research Institute, La Jolla, CA Harold L. Dorris Neurological Research Center and Scripps Research Institute, La Jolla, California, USA
  • Graham Lees, PhD, Publishing Consultant, Corpus Alienum Oy, Finland

Everyone expects something from the drug industry. Physicians and patients, investors, regulators and administrators all have an active interest. Everyone wants to know what makes drugs ‘work’ medically and economically. Why are drugs so expensive? Is it the drug companies or investors who demand high profits? What governs the pharmacoeconomics? Why are so few diseases treatable? This book opens the windows and doors of the industry telling the story of drug development by using real stories from inside the process.
View full description


Academics/Scientists interested in working with biotech and pharma companies


Book information

  • Published: December 2005
  • ISBN: 978-0-12-369533-8


"Doody's 3 Star Review: It was refreshing reading about these matters from a different perspective. The critical nature of the book, I would imagine, was intentional to play the proverbial "devil's advocate". This book truly caused me to rethink some attitudes and opinions I have had about pharmaceutical company behavior in the marketplace. It's nice that once in a while such a refreshing publication comes along." - Albert Wertheimer, B.S., MBA, PhD, Temple University School of Pharmacy for DOODY'S "[This book] is very readable and insightful. I am hopeful that many people will pick it up, and develop a better appreciation for what goes into making the treatments that everyone wants!" - Dennis W. Choi, M.D., Sr. VP Merck (2006) "Anyone who thinks solutions to drug development are just around the corner would be well-advised to get this insider's views as to where the real problems lie." - Floyd Bloom, CEO Neurome, former Editor of Science magazine (2006) "...a very informative and exciting book filling an important niche. Very easy to read, it encouraged me to think about several things." - Richard Nass, Vanderbilt University (2006)

Table of Contents

Proposed Contents:1. The Art of Putting a Molecule Into Man2. Raising & Rising Expectations3. History is good to know4. The "Better Betablocker Barrier"5. Why Some Good Drugs Do Not Get a Chance & Why6. About the Economics of Target and Clinical Candidate Selection7. Target Based Drug Discovery: Part I8. Changes Need to be Made9. Target Based Drug Discovery, Part II10. "Drugable" Targets11. So Many Drugs, So Few Entities12. How to Find a Candidate13. Practicalities: The Hoops & Hurdles of Big Pharma14. Practical Trials for a Balanced Portfolio15. How to Improve the Odds of Finding a Safe Drug that Works16. The Tribulations of Clinical Trials17. Linking Putative Targets to Disease States18. More Ways to Look for Targets19. The Business Basics20. Adding Value in a Growth of Industry21. What's the Most Profitable Approach?22. Pharmacoeconomics for Biotech23. Shrinking Value of Targets24. Assessing Company Assets? Look in the Library25. To Merge or Not to Merge?26. Working with the Food & Drug Administration (FDA)27. Regulating Regulatory Regimens Reliably28. The Hypothesis Is: There is a Better Way29. What are "We" all Working on?30. More Tablets Taken per Day than Meals Served